Tổng quan dấu ấn sinh học mới MR-proANP trong suy tim cấp

[1] B. Casserly, R. Read, M. M. Levy, “Hemodynamic Monitoring in Sepsis,” Crit Care Clin, (25), pp. 803-823, 2009. DOI: 10.1016/j.ccc.2009.08.006

[2] Đ. V. Phước, “Suy tim trong thực hành lâm sàng,” Thành phố Hồ Chí Minh: Nhà xuất bản Đại học Quốc Gia, tr. 15 - 62, 2014.

[3] L. X. Trường, “Những xét nghiệm hóa sinh hiện đại sử dụng trong lâm sàng,” Thành phố Hồ Chí Minh: Nhà xuất bản Y học, chi nhánh TP. Hồ Chí Minh, 2015.

[4] N. Proudfoot, “The end of the message,” Nature, (298), pp. 516-517, 1982.

[5] A. J. de Bold, H. B. Borenstein, A. T. Veress, H. Sonnenberg, “A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats,” in Life Sci, pp. 89 - 94, 1991. DOI: 10.1016/0024-3205(81)90370-2

[6] D. Westermann, D. Lindner, M. Kasner, C. Zietsch, K. Savvatis, F. Escher, J. V. Schlippenbach, C. Skurk, P. Steendijk, A. Riad, W. Poller, H. P Schultheiss, C. Tschope, “Cardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fraction,” Circ Heart Fail, (4), pp. 44-52, 2011. DOI: 10.1161/CIRCHEARTFAILURE.109.931451

[7] A. Mosterd, B. Cost, A. W. Hoes, M. C. de Bruijne, J. W. Deckers, A. Hofman, D. E. Grobbee, “The prognosis of heart failure in the general population. The Rotterdam Study,” Eur Heart J, pp. 1318 - 1327, 2001. DOI: 10.1053/euhj.2000.2533

[8] G. Thibault, F. Amiri, R. Garcia, “Regulation of natriuretic peptide secretion by the heart,” Annu Rev Physiol, pp. 193 - 217, 1999. DOI: 10.1146/annurev.physiol.61.1.193

[9] D. L. Kasper, S. L. Hauser, J. L. Jameson, “Chapter 279. Heart Failure: Pathophysiology and Diagnosis," In: Harrison's Principles of Internal Medicine, Mc-Graw-Hill Companies, Inc, 19th. Edition, pp. 1500, 2015.

[10] H. Ruskoaho, “Atrial natriuretic peptides: synthesis, release and metabolism,” Pharmacol Rev, pp. 497 - 602, 1992.

[11] R. E. Lang, H. Tholken, D. Ganten, F. C. Luft, H. Ruskoaho, Th. Unger, “Atrial natriuretic factor-a circulating hormone stimulated by volume loading,” Nature, pp. 264 - 266, 1985.

[12] H. Roskoaho, H. Tholken, R. E. Lamg, “Increase in atrial pressure releases atrial natriuretic peptide from isolated perfused rat hearts,” Pfluegers Arch, pp. 170 - 174, 1986. DOI: 10.1007/BF00580671

[13] P. Kinnunen, O. Vuolteenaho, P. Uusimaa, H. Ruskoaho, “Passive mechanical stretch releases atrial natriureic peptide from rat ventricular myocardium,” Cir Res, pp. 1244 - 1253, 1992. DOI: 10.1161/01.res.70.6.1244

[14] H. Ruskaoho, P. Kinnunen, T. Taskinen, O. Vuolteenaho, J. Leppaluoto, T. E. Takala, “Regulation of ventricular of ventricular atrial natriuretic peptide release in hypertrophied rat myocardium. Effects of exercise,” Circulation, pp. 390 - 400, 1989. DOI: 10.1161/01.CIR.80.2.390

[15] A. J. de Bold, B. G. Bruneau, M. L. K. de Bold, “Mechanical and neuroendocrine regulation of the endocrine heart,” Cardiovasc Res, pp. 7 - 18, 1996.

[16] G. Thibault, M. Nemer, J. Drouin, J. P. Lavigne, J. Ding, C. Charbonneau, R. Garcia, J. Genest, G. Jasmin, M. Sole, “Ventricles as a major site of atrial natriuretic factor synthesis and release in cardiomyopathic hamsters with heart failure,” Cir Res, pp. 71 - 82, 1989. DOI: 10.1161/01.RES.65.1.71

[17] H. Yasue, K. Obata, K. Okumura, M. Kurose, H. Ogawa, K. Matsuyama, M. Joigasaki, Y. Saito, K. Nakao, H. Imura, “Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy,” J Clin Invest, pp. 46 - 51, 1989. DOI: 10.1172/JCI113883

[18] H. Mangat and A. J. de Bold, “Stretch - induced atrial natruretic factor release utilizers a rapidly depleting pool of newly synthesized hormone,” Endocrinology, pp. 1398 - 1403, 1993. DOI: 10.1210/endo.133.3.8365374

[19] C. C. Lang, A. M. Choy, K. Turner, R. Tobin, W. Coutie, A. D. Struthers, “The effect of intravenous saline loading on plasma levels of brain natriureic peptide in man,” J Hypertens, pp. 737 - 741, 1993. DOI: 10.1097/00004872-199307000-00009

[20] A. M. Richards, G. Crozier, E. A. Espiner, T. G. Yandle, M. G. Nicholls, “Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension,” Hypertension, pp. 231 - 236, 1993. DOI: 10.1161/01.HYP.22.2.231

[21] A. J. de Bold, K. K. Ma, Y. Zhang, M. L. de Bold, M. Bensimon, A. Khoshbaten, “The physiological modulation of the endocrine function of the heart,” Can J Physiol Pharmacol, pp. 705 - 714, 2001.

[22] B. G. Bruneau, L. A. Piazza, A. J. de Bold, “BNP gene expression is specifically modulated by stretch and ET-1 in a new model of isolated rat atria,” Am J Physiol, pp. 2678 - 2686, 1997. DOI: 10.1152/ajpheart.1997.273.6.H2678

[23] H. Leskinen H, O. Voulteenaho, H. Ruskoaho, “Combined inhibitionon endothelin and angiotensin II receptor block volume load-induced cardiac hormonerelease,” Cir Res, pp. 114 - 123, 1997. DOI: 10.1161/01.res.80.1.114

[24] T. Ogawa, W. Linz, M. Stevenson, B. G. Bruneau, M. L. K. de Bold, J. H. Chen, H. Eid, B. A. Scholkens, A. J. de Bold, “Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production,” Circulation, pp. 2059 - 2067, 1996. DOI: 10.1161/01.cir.93.11.2059

[25] H. Ruskaoho, H. Leskinen, J. Magga, P. Taskinen, P. Mantymaa, O. Vuolteenaho, J. Leppaluoto, “Mechanism of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide and angiotensin II,” J Mol Med, pp. 876 - 885, 1997. DOI: 10.1007/s001090050179

[26] F. Ichinose, E. S. Buys, T. G. Neilan, E. M. Furutani, J. G. Morgan, D. S. Jassal, A. R. Graveline, R. J. Searles, C. C. Lim, M. Kaneki, M. H. Picard, M. Scherrer-Crosbie, S. Janssens, R. Liao, K. D. Bloch, “Cardio-myocyte-specific overexpression of nitric oxide synthase 3 prevents myocardial dysfunction in murine models of septic shock,” Circ Res, (100), pp. 130-139, 2007. DOI: 10.1161/01.RES.0000253888.09574.7a

[27] S. S. Gottlieb, M. L. Kukin, D. Ahern, M. Packer, “Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure,” J Am Coll Cardial, pp. 1334 - 1339, 1989. DOI: 10.1016/0735-1097(89)90344-6

[28] J. Mair, A. Hammerer-Lercher, B. Puschendorf, “The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure,” Clinical Chemistry & Laboratory Medicine, pp 571 - 588, 2001. DOI: 10.1515/CCLM.2001.093

[29] J. A. Smith, D. Bruusgaard, E. Bodd, C. Hall, “Relations between medical history, clinical findings and plasma N-terminal proatrial natriuretic peptide in patients in primary health care,” European Journal of Heart Failure, pp. 307 - 313, 2001. DOI: 10.1016/s1388-9842(01)00124-6

[30] A. Maisel, C. Mueller, R. Nowak, W. F. Peacock, J. W. Landsberg, P. Ponikowski, M. Mockel, C. Hogan, A. H. B. Wu, M. Richards, P. Clopton, G. S. Filippatos, S. D. Somma, I. Anand, L. Ng, L. B. Daniels, S. X. Neath, R. Christenson, M. Potocki, J. McCord, G. Terracciano, D. Kremastinos, O. Hartmann, S. V. Haehling, A. Bergmann, N. G. Morgenthaler, S. D. Anker, “Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkersin Acute Heart Failure) trial,” J Am Coll Cardiol (55), pp. 2062-2076, 2010. DOI: 10.1016/j.jacc.2010.02.025

[31] Yang Chen, Zheqi Wen, Long Peng, Xing Liu, Yanting Luo, Bingyuan Wu & Suhua Li, “Diagnostic value of MR-proANP for heart failure in patients with acute dyspnea: A meta-analysis”, Acta Cardiologica, pp 68-74, 2020. DOI: 10.1080/00015385.2018.1550887

[32] T. Omland, V. V. Bonarjee, R. T. Lie, K. Caidahl, “Neurohormoral measurements as indicators of long-term prognosis after acute myocardio infarction,” Am J Cardiol, pp. 230 - 235, 1995. DOI: 10.1016/s0002-9149(99)80071 - x.

[33] K. M Davis, L. C. Fish, D. Elahi, B. A. Clark, K. L. Minaker, “Atrial natriuretic peptide levels in the prediction of congestive heart failure risk in frail elderly,” JAMA, pp. 2625 - 2629, 1992. [34] N. G. Morgenthaler, J. Struck, B. Thomas, A. Bergmann, “Immunometric assay for the mid regional of pro-atrial natriuretic peptide in human plasma,” Clinical Chem, (50), pp. 234 - 236, 2004. DOI: 10.1373/clinchem.2003.021204

[35] C Zelenak, M.L Chavanon, E. Tahirovic, “Early NT-proBNP and MR-proANP associated with QoL 1 year after acutely decompensated heart failure: secondary analysis from the MOLITOR trial”, Biomark. Med, 13(17), pp.1493 - 1507, 2019.

[36] B. M. Y. Cheung and C. R. Kumana, “Natriuretic peptides - revelance in cardiac disease”, JAMA. pp. 1983 - 1984, 1998. DOI:10.1001/jama.280.23.1983

[37] S.V.Haehling, E.A.Jankowska,N.G.Morgenthaler,… S.D.Anker, “Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure”, Journal of the American College of Cardiology, Vol.50, No.20, pp.1973 - 1980, 2007. DOI:10.1016/j.jacc.2007.08.012

[38] Zekun Feng, Olumuyiwa P. Akỉnimisi, Jeffrey A.Gornbein, Quynh A. Truong, Saumyadas, Jagmeet P.Singh, Olujimiajijola, “Combination Biomarkers for Risk Stratification in Patients With Chronic Heart Failure Biomarkers Prog-nostication in HF”, Journal of Cardiac Failure, 2021, DOI: 10.1016/j.cardfail.2021.05.028

[39] L. B. Daniels, P. Clopton, M. Potocki, J. McCord, M. Richards, O. Hartmann, I. S. Anand, A. H. B. Wu, R. Nowak, W. F. Peacock, P. Ponikowski, M. Mockel, C. Hogan, G. S. Filippatos, S. D. Somma, L. Ng, S. X. Neath, R. Christenson, N. G. Morgenthaler, S. D. Anker, A. S. Maisel, “Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study,” European Journal of Heart Failure, 14, pp. 22-31, 2012. DOI: 10.1093/eurjhf/hfr157

[40] N. G. Morgenthaler, J. Struck, B. Thomas, A. Bergmann, “Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma,” Clinical Chem, 50, pp. 234 - 236, 2004. DOI:10.1373/clinchem.2003.021204